“Elotuzumab: The First Available Immunotherapeutic Arrow Against Relapsed-Refractory Multiple Myeloma”. 2017. European Journal of Oncology and Environmental Health 22 (2): 65-70. https://mattioli1885journals.com/index.php/EJOEH/article/view/6857.